Jushi Holdings Inc., a vertically integrated, multistate cannabis operator, has submitted applications to the U.S. Drug Enforcement Administration (DEA) seeking DEA registration for certain state-licensed medical cannabis operations. This move follows the federal reclassification of medical marijuana to Schedule III under the Controlled Substances Act, as reported by Cannabis Business Times on May 28, 2026. The applications aim to integrate Jushi’s operations within the evolving federal regulatory framework for medical cannabis.
Federal Schedule III Framework and DEA Registration
The reclassification of medical marijuana to Schedule III has introduced a streamlined registration pathway for qualified state-licensed medical cannabis operators. This process allows applicants to seek federal registration for the manufacture, distribution, and dispensing of Schedule III medical cannabis products, leveraging existing state medical licenses for qualification. Operators submitting applications within the initial 60-day filing window may receive expedited registration approval from the DEA.
Jushi Holdings Inc. CEO Jim Cacioppo stated that pursuing DEA registration represents an important milestone for the company and the medical patients it serves. He emphasised the company’s focus on operating at high regulatory standards and views this process as a meaningful step toward a more integrated and transparent national framework for medical cannabis.
Implications for State-Licensed Medical Cannabis Operations
This federal framework is seen by Jushi as reflecting an increasing federal recognition of the oversight and strength of state medical cannabis programs. It provides a pathway toward greater alignment between state and federal regulation, a development that has been anticipated by industry stakeholders. The company’s applications are intended to position Jushi to participate effectively in this evolving regulatory structure while continuing to serve medical patients in accordance with applicable state laws.
The move by Jushi follows similar actions by other industry players, such as Cresco Labs secured DEA registrations for certain state-licensed medical cannabis facilities, as previously reported by Hemp Gazette. These developments underscore a broader industry trend towards federal compliance and integration following the Schedule III reclassification.
Market and Regulatory Landscape
The reclassification of medical cannabis to Schedule III under the Controlled Substances Act marks a significant shift in the U.S. regulatory landscape.
Mr. Cacioppo also noted that this step reinforces feedback from patients regarding their experience with medical cannabis. He expressed the company’s anticipation of engaging with regulators as this framework develops, supporting continued progress in:
- Research into medical cannabis efficacy and safety.
- Enhancing patient access to regulated medical cannabis products.
- Ensuring responsible oversight of medical cannabis in the United States.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
